Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery, orthopaedics and dental markets. 2021 results contained the early benefits of TRX’s strategic activities over the past two years – the focus on commercial relationships, capacity expansion, restructuring to service demand and recovery in elective surgeries. On the basis of continued sales progression, TRX is forecast to become EBITDA-positive in fiscal 2022 and cash-generative in 2023.
19 Apr 2022
Tissue Regenix (TRX): On pathway to sustainability
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Tissue Regenix (TRX): On pathway to sustainability
- Published:
19 Apr 2022 -
Author:
Martin Hall -
Pages:
16
Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery, orthopaedics and dental markets. 2021 results contained the early benefits of TRX’s strategic activities over the past two years – the focus on commercial relationships, capacity expansion, restructuring to service demand and recovery in elective surgeries. On the basis of continued sales progression, TRX is forecast to become EBITDA-positive in fiscal 2022 and cash-generative in 2023.